Keyphrases
Bacteremia
43%
Endocarditis
40%
Cryptococcus Gattii
37%
Early Clinical Exposure
37%
HIV-associated Lymphoma
37%
Delafloxacin
37%
Texas
37%
Erysipelothrix Rhusiopathiae
37%
Fish Handlers
37%
Fungal Infection
37%
Meningitis
37%
Cryptococcal Osteomyelitis
37%
Novel Antibiotics
37%
Cryptococcal Infection
37%
Valve Endocarditis
37%
Immune Reconstitution
37%
Viral Load
37%
CD4 Count
37%
Antibiotic Combination
37%
Eustachian Valve
37%
Nosocomial Pneumonia
37%
Carbapenem-resistant Acinetobacter Baumannii
37%
Lymphoma Diagnosis
29%
Immune System
24%
Staphylococcus Epidermidis (S. epidermidis)
21%
Gattii
18%
Early Recognition
18%
Severe Infection
18%
40 Years Old
18%
Immunocompetent Individual
18%
Early Treatment
18%
Non-endemic
18%
Disease Progression
18%
Cefiderocol
18%
Autopsy
18%
Young Males
18%
Development Effort
18%
Septic Shock
18%
Extensively Drug-resistant
18%
Drug Development
18%
Poor Outcome
18%
Expanded Access
18%
Nosocomial Infection
18%
Acinetobacter Baumannii (A. baumannii)
18%
Baumannii
18%
Pneumonia
18%
Oncology Clinic
14%
HIV Patients
14%
Downtrend
14%
Infectious Complications
14%
Medicine and Dentistry
Infection
100%
Endocarditis
74%
Human Immunodeficiency Virus
55%
Bloodstream Infection
45%
Antibiotics
37%
Mycosis
37%
Osteomyelitis
37%
Erysipelothrix rhusiopathiae
37%
Delafloxacin
37%
Meningitis
37%
Immune Reconstitution Inflammatory Syndrome
37%
Cryptococcus gattii
37%
Acinetobacter Baumannii
37%
Antimicrobial Agent
37%
Immune System
24%
Disease Exacerbation
18%
Cefiderocol
18%
Awareness
18%
Penicillin Derivative
18%
Septic Shock
18%
Disease
18%
Hospital Infection
18%
Quinolone Derivative
13%
Staphylococcus Epidermidis
12%
Methicillin-Resistant Staphylococcus Epidermidis
12%
Conservative Treatment
12%
Secondary Infection
12%
Neurological System
12%
Side Effect
10%
Ceftriaxone
9%
Pathogenic Organism
9%
Valve Replacement
9%
Mitral Valve
9%
Gram-Positive Bacteria
9%
Aortic Valve
9%
Congestive Heart Failure
9%
Oncology
6%
Infectious Complication
6%
Lymphocyte
6%
Cryptococcosis
6%
Human Immunodeficiency Virus Infection
6%
Drug Therapy
6%
Pharmacology, Toxicology and Pharmaceutical Science
Infection
55%
Delafloxacin
37%
Acinetobacter Baumannii
37%
Endocarditis
37%
Antibiotic Agent
37%
Cryptococcus gattii
37%
Meningitis
37%
Erysipelothrix rhusiopathiae
37%
Mycosis
37%
Bloodstream Infection
37%
Antimicrobial Agent
37%
Disease Exacerbation
18%
Disease
18%
Septic Shock
18%
Hospital Infection
18%
Penicillin Derivative
18%
Drug Development
18%
Cefiderocol
18%
Quinolone Derivative
13%
Gram Positive Bacterium
9%
Ceftriaxone
9%
Congestive Heart Failure
9%